CJC-1295 No Dac

CJC-1295 No DAC 10 mg is offered by SARMs Revolution Lab for laboratory research in Canada. The “No DAC” distinction is important: it indicates a product marketed without the Drug Affinity Complex used to extend the activity of long-acting CJC-1295 studied in early clinical research.

CJC-1295 No DAC 10 mg research product information

Sequence, identity, concentration and analytical documentation should be checked on a batch basis. “CJC-1295” and “CJC-1295 No DAC” should not be treated as interchangeable names.

What is CJC-1295 No DAC?

CJC-1295 is associated with research on analogues of growth hormone-releasing hormone. The DAC modification was designed to bind albumin and extend exposure. Products marketed as “No DAC” are generally discussed as shorter-acting GHRH-related research peptides, but naming conventions in the commercial market are inconsistent.

Because nomenclature varies, researchers should confirm the actual sequence and analytical identity rather than relying only on the product title.

What does the published CJC-1295 evidence cover?

A randomized study in healthy adults examined a long-acting CJC-1295 analogue and reported prolonged changes in GH and IGF-1. That study involved the DAC-containing form and cannot be used as direct evidence for a No-DAC 10 mg vial.

Research may examine receptor signalling, peptide stability, degradation and analytical identity. This page does not claim improved sleep, muscle gain, recovery, fat loss or performance and does not provide a human-use protocol.

CJC-1295 No DAC evidence limits in Canada

Experimental peptides should not be represented as authorized therapies solely because a related molecule appeared in a clinical trial. Product authorization, formulation and indication must be verified independently.

CJC-1295 No DAC 10 mg frequently asked questions

What does “No DAC” mean?

It indicates that the product is marketed without the Drug Affinity Complex used in the long-acting form of CJC-1295.

How much material is supplied?

The SRL listing identifies one 10 mg vial. Review the product label and batch documentation.

Can the DAC clinical trial be applied to CJC-1295 No DAC?

Not directly. The structural distinction affects exposure and is central to interpreting the evidence.

Is CJC-1295 No DAC proven for muscle or fat loss?

No. Mechanistic and related clinical findings do not establish those outcomes for this product.

Does this page provide dosing or combination advice?

No. It does not provide dosage, reconstitution, administration or stacking instructions.

Where can related GHRH research be reviewed?

See the Tesamorelin research page, the Ipamorelin research page and the SRL peptide category. These links do not recommend combining products.

Scientific reference

• Teichman SL et al. Clinical research on long-acting CJC-1295 with DAC in healthy adults. 2006.

Research-use notice: CJC-1295 No DAC 10 mg is offered strictly for laboratory research and analytical work. It is not intended for human consumption, self-administration, diagnosis, treatment or veterinary use.